NorthWest Biotherapeutics Inc (NWBO)

[Truthfan]

“We are also investigating other immune system pathways in the treatment of cancer including CTLA-4, CD-137, KIR, SLAMF7, PD-1, GITR, CSF1R, IDO, and LAG-3. These pathways may lead to potential new treatment options – in combination or monotherapy – to help patients fight different types of cancers.
Our collaboration with academia, as well as small and large biotech companies, to research the potential Immuno-Oncology and non-Immuno-Oncology combinations, helps achieve our goal of providing new treatment options in clinical practice.”

Segment of Press Release from BMY September 20, 2016

http://investor.bms.com/investors/news-and-events/press-releases/press-release-details/2016/European-Medicines-Agency-Validates-Bristol-Myers-Squibbs-Type-II-Variation-Application-for-Opdivo-nivolumab-in-Advanced-Form-of-Bladder-Cancer/default.aspx